おすすめの製品
由来生物
synthetic
グレード
pharmaceutical primary standard
認証
EP
APIファミリー
phytomenadione
フォーム
solid
メーカー／製品名
EDQM
テクニック
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
屈折率
n20/D 1.527 (lit.)
mp
−20 °C (lit.)
密度
0.984 g/mL at 25 °C (lit.)
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
O=C(C1=CC=CC=C21)C(C)=C(C/C=C(CCC[C@@H](CCC[C@H](C)CCCC(C)C)C)\C)C2=O
InChI
1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1
InChI Key
MBWXNTAXLNYFJB-NKFFZRIASA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Phytomenadione is a methyl napthoquinone derivative, and a naturally occurring fat soluble vitamin K1. It plays a key role in the maintenance of normal blood clotting mechanism and also in the prevention of hemorrhagic disease in newborns.
Phytomenadione is a methyl napthoquinone derivative, and a naturally occurring fat soluble vitamin K1. It plays a key role in the maintenance of normal blood clotting mechanism and also in the prevention of hemorrhagic disease in newborns.
アプリケーション
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
保管分類コード
11 - Combustible Solids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
この製品を見ている人はこちらもチェック
Clinical Pharmacology, (11) (2012)
Development and validation of spectrophotometric methods for determination of phytomenadione in injection
Patel AS and Parikh KP
Current Research in Pharmaceutical Sciences, 26-30 (2012)
Ellen C M Cranenburg et al.
Kidney international, 82(5), 605-610 (2012-06-01)
Vitamin K is essential for the activity of γ-carboxyglutamate (Gla)-proteins including matrix Gla28 protein and osteocalcin; an inhibitor of vascular calcification and a bone matrix protein, respectively. Insufficient vitamin K intake leads to the production of non-carboxylated, inactive proteins and
Rogier Caluwé et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(7), 1385-1390 (2013-11-29)
Haemodialysis patients suffer from accelerated vascular calcification. The vitamin K-dependent matrix Gla protein (MGP) is one of the most powerful inhibitors of vascular calcification. Haemodialysis patients have high levels of the inactive form of MGP (desphosphorylated-uncarboxylated-MGP, dp-uc-MGP) and may benefit
Bernard Laubscher et al.
European journal of pediatrics, 172(3), 357-360 (2012-11-30)
In 2003, the Swiss guidelines to prevent vitamin K deficiency bleeding (VKDB) were adapted. As two oral doses (2 mg, hour/day 4) of mixed micellar VK preparation had failed to abolish late VKDB, a third dose (week 4) was introduced.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）